EUVIMEDEUVIMED entdecken
Crossref

Association of Pneumonia, Fracture, Metabolic, and Renal Events With Long‐Term Proton Pump Inhibitor Use in Patients With Chronic Kidney Disease

Yi-Fan Chien iD, Yun-Yi Chen iD, Chung-Kuan Wu iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025

DOI: 10.1002/phar.70043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2025. Verfasst von Yi-Fan Chien und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Medicine, Cathay General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Renal Insufficiency, Chronic, Pneumonia, Fractures, Bone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Shin-Kong Wu Ho-Su Memorial Hospital Research Foundation (Number SKH-8302-103-DR-06), Shin Kong Wu Ho-Su Memorial Hospital and National Yang-Ming University in Taiwan (109GB006-2).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Proton pump inhibitors (PPIs) have been commonly used for gastroesophageal reflux disease (GERD) and peptic ulcers (PU), which are even more prevalent in patients with chronic kidney disease (CKD). Although PPI‐related adverse outcomes are well documented in the general population, evidence in patients with CKD remains limited. This study investigated the associations of PPI use and adverse outcomes in patients with CKD who had GERD or PU.

Methods

In this nationwide, retrospective cohort study, patients with CKD and also PU or GERD from 2006 to 2015 were enrolled and sorted into no‐, short‐term, and long‐term PPI groups. Incidence and risks of outcome events between these three groups were analyzed with the Cochran‐Armitage test and Cox proportional hazard analyses. Events‐free probability was estimated with the Kaplan–Meier method during follow‐up.

Results

In the study, 384,411 patients with CKD with PU or GERD were enrolled. The numbers of no‐, short‐term, and long‐term PPI treatments were 147,976, 14,153, and 3459, respectively. Relative to the no‐PPI group, the adjusted hazard ratios (aHRs) of admission for pneumonia and fracture, new diagnosis of type 2 diabetes mellitus (DM), and progression to end‐stage kidney disease (ESKD) in the short‐term (1.089, 1.083, 1.175, 1.22) and long‐term PPI groups (1.882, 2.601, 1.951, 1.714) remained statistically significant, respectively, even after adjustment for significant baseline variables; the aHR of dialysis was significant only in the long‐term PPI group. Kaplan–Meier analysis revealed significant outcome events in the long‐term PPI group during follow‐up.

Conclusion

PPI use is associated with an increased risk of pneumonia, fracture, incidence of type 2 DM, and progression to ESKD in patients with CKD, and the risk increases substantially with increased duration of PPI use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proton Pump InhibitorsRenal Insufficiency, ChronicPneumoniaFractures, BoneHumansMaleFemaleRetrospective StudiesMiddle AgedAgedGastroesophageal RefluxPeptic UlcerCohort StudiesIncidenceDiabetes Mellitus, Type 2

Stichwörter der Autor:innen

chronic kidney diseasesdiabetic mellitusdialysisfracturepneumoniaproton pump inhibitor

Substanzen

Proton Pump Inhibitors

Autor:innen und Institutionen

  • Division of General Medicine, Cathay General Hospital, Taipei, Taiwan.
  • Institute of Hospital and Health Care Administration, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Department of Research, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
  • Division of Nephrology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
  • School of Medicine, Fu-Jen Catholic University, New Taipei, Taiwan.

ORCID-Profile: Yi-Fan Chien, Yun-Yi Chen, Chung-Kuan Wu

Förderung

  • Shin-Kong Wu Ho-Su Memorial Hospital Research Foundation (Number SKH-8302-103-DR-06)
  • Shin Kong Wu Ho-Su Memorial Hospital and National Yang-Ming University in Taiwan (109GB006-2)

Zitieren

APA

Chien, Y. F., Chen, Y. Y., & Wu, C. K. (2025). Association of Pneumonia, Fracture, Metabolic, and Renal Events With Long‐Term Proton Pump Inhibitor Use in Patients With Chronic Kidney Disease. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70043

Vancouver

Chien YF, Chen YY, Wu CK. Association of Pneumonia, Fracture, Metabolic, and Renal Events With Long‐Term Proton Pump Inhibitor Use in Patients With Chronic Kidney Disease. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025. doi:10.1002/phar.70043

BibTeX
@article{Chien2025,
  author = {Chien, Yi-Fan and Chen, Yun-Yi and Wu, Chung-Kuan},
  title = {Association of Pneumonia, Fracture, Metabolic, and Renal Events With Long‐Term Proton Pump Inhibitor Use in Patients With Chronic Kidney Disease},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2025},
  doi = {10.1002/phar.70043}
}
Kostenlos starten →